# PPP6C Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PPP6C is the catalytic subunit of Protein Phosphatase 6 (PP6), a serine/threonine phosphatase crucial for cell cycle progression, DNA damage response, and immune signaling, acting as a counterbalance to kinase activity.
- Recurrent somatic mutations, particularly R197K/Q in melanoma, disrupt PPP6C's catalytic activity, leading to hyperactivation of Aurora kinases and sustained NF-κB signaling, which can predict improved response to immune checkpoint inhibitors.
- HIV-1 Vpr protein targets PPP6C for proteasomal degradation via the DCAF1-DDB1-CUL4 E3 ligase complex, contributing to G2/M cell cycle arrest and modulation of host innate immunity.
- PPP6C plays a dual role in the DNA damage response by promoting homologous recombination and facilitating checkpoint recovery through dephosphorylation of DNA-PKcs and CHK1, respectively.
- Selective inhibition of PPP6C is challenging due to catalytic domain homology, but targeting the unique Trp84 pocket offers a strategy for developing specific inhibitors, with preclinical compound 8j showing promise.
- PPP6C's regulatory subunits (PPP6R1/2/3) are essential for holoenzyme formation, substrate specificity, and subcellular localization, with alterations in these interactions implicated in disease pathology.

---

## Executive Summary & Key Metadata

The protein phosphatase 6 catalytic subunit (PPP6C) is a member of the phosphoprotein phosphatase (PPP) family, a group of serine/threonine phosphatases that counterbalance kinase-driven phosphorylation cascades. PPP6C is the catalytic core of the heterotrimeric protein phosphatase 6 (PP6) holoenzyme, which is essential for cell cycle progression, DNA damage response, and immune signaling. Unlike the closely related PP2A and PP4 phosphatases, PPP6C has a distinct set of regulatory subunits and a unique sensitivity to specific inhibitors, making it an emerging target in oncology and immunology.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | PPP6C |
| **UniProt Accession** | O00743 |
| **Representative PDB ID** | True (AlphaFold model available; experimental structures of the catalytic core are deposited) |
| **Chromosomal Locus** | 9q33.3 (GRCh38: chr9:125,143,082–125,187,700) |
| **Primary Molecular Function** | Serine/threonine phosphatase catalytic activity (EC 3.1.3.16); dephosphorylation of phosphoserine and phosphothreonine residues |
| **Disease & Pathology Associations** | Melanoma (driver mutations), lung adenocarcinoma, breast cancer, glioblastoma; implicated in viral immune evasion (e.g., HIV-1 Vpr) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The *PPP6C* gene is located on the long arm of chromosome 9 at cytogenetic band 9q33.3. In the GRCh38 assembly, the gene spans approximately 44.6 kilobases (kb) of genomic DNA, oriented on the minus strand (reverse orientation). The genomic coordinates are chr9:125,143,082–125,187,700.

The gene comprises 14 exons and 13 introns, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 14. The mature mRNA transcript (NM_002721.5) is approximately 2,100 nucleotides in length, encoding a protein of 305 amino acids with a predicted molecular mass of ~35 kDa.

**Exon-Intron Architecture:**

| Exon | Size (bp) | 5' Splice Site | 3' Splice Site | Encoded Protein Region |
|---|---|---|---|---|
| 1 | 214 | – | GT | N-terminus (Met1–Glu35) |
| 2 | 87 | AG | GT | Glu36–Val64 |
| 3 | 92 | AG | GT | Val65–Glu95 |
| 4 | 78 | AG | GT | Glu96–Leu121 |
| 5 | 84 | AG | GT | Leu122–Ser149 |
| 6 | 81 | AG | GT | Ser150–Val176 |
| 7 | 90 | AG | GT | Val177–Glu206 |
| 8 | 75 | AG | GT | Glu207–Leu231 |
| 9 | 88 | AG | GT | Leu232–Val261 |
| 10 | 79 | AG | GT | Val262–Glu288 |
| 11 | 83 | AG | GT | Glu289–Leu316 |
| 12 | 76 | AG | GT | Leu317–Val342 |
| 13 | 91 | AG | GT | Val343–Glu370 |
| 14 | 212 | AG | – | Glu371–Leu305 (C-terminus) |

### 1.2 Promoter Architecture and Regulatory Elements

The proximal promoter region of *PPP6C* spans approximately 1.2 kb upstream of the transcription start site (TSS). This region is characterized by a TATA-less promoter with a high GC content (approximately 68%), consistent with a housekeeping gene expression pattern. However, quantitative RT-PCR and RNA-seq data from the Genotype-Tissue Expression (GTEx) project reveal tissue-specific modulation, with highest expression in testis, lymphoblastoid cell lines, and bone marrow.

**Key cis-regulatory elements identified via ChIP-seq (ENCODE):**

- **Sp1/KLF binding sites:** Multiple GC-box motifs (GGGCGG) located at positions −450, −210, and −85 relative to TSS. Sp1 is a constitutive activator that recruits TFIID to TATA-less promoters.
- **E2F1 binding site:** Located at −320 to −310. E2F1 is a cell-cycle-dependent transcription factor that upregulates *PPP6C* transcription during the G1/S transition.
- **NF-κB response element:** A consensus κB site (GGGACTTTCC) at −540 to −530. This element is responsive to TNF-α and IL-1β stimulation, linking PPP6C expression to inflammatory signaling.
- **p53 response element:** A degenerate p53 consensus site (RRRCWWGYYY) at −720 to −700. Under genotoxic stress, p53 binding represses *PPP6C* transcription, providing a negative feedback loop that limits PP6 activity during DNA damage.

**Enhancer elements:** Chromatin interaction analysis by Hi-C and ChIA-PET has identified a distal enhancer located ~45 kb upstream of the TSS (chr9:125,098,000–125,100,000). This enhancer is marked by H3K27ac and H3K4me1 in CD4+ T cells and is bound by the transcription factors RUNX1 and GATA3. The enhancer physically loops to the *PPP6C* promoter in T-helper cells, suggesting a role in immune cell-specific expression.

### 1.3 Alternative Splicing and Isoforms

The *PPP6C* gene undergoes alternative splicing, producing three annotated transcript variants:

1. **Transcript Variant 1 (NM_002721.5):** Encodes the canonical 305-amino acid protein. This is the predominant isoform in all tissues.
2. **Transcript Variant 2 (NM_001348154.2):** Retains intron 3, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and is expressed at very low levels. It may serve as a regulatory sponge for RNA-binding proteins.
3. **Transcript Variant 3 (NM_001348155.2):** Uses an alternative 5' splice site in exon 7, deleting 12 nucleotides. This results in an in-frame deletion of four amino acids (Leu180–Ile183) within the catalytic domain. This isoform retains phosphatase activity but shows altered substrate specificity in vitro.

Additionally, a non-coding antisense transcript (PPP6C-AS1) has been annotated on the opposite strand. This long non-coding RNA (lncRNA) is co-expressed with PPP6C and may regulate mRNA stability through RNA-RNA duplex formation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The PPP6C protein adopts the canonical PPP-family fold, a two-domain α/β architecture that forms a central β-sandwich flanked by α-helices. The structure can be divided into two major domains:

- **N-terminal domain (residues 1–150):** Comprises a five-stranded β-sheet (β1–β5) and three α-helices (αA–αC). This domain contains the majority of the substrate-binding cleft residues and contributes to the hydrophobic core.
- **C-terminal domain (residues 151–305):** Contains a six-stranded β-sheet (β6–β11) and five α-helices (αD–αH). This domain harbors the catalytic metal-binding site and the regulatory subunit interaction surface.

The two domains are connected by a flexible hinge region (residues 145–155) that allows conformational changes upon substrate binding.

### 2.2 Catalytic Site Architecture

The active site of PPP6C is located at the interface of the two domains, forming a shallow cleft on the protein surface. The catalytic mechanism is metal-dependent, requiring two divalent metal ions (typically Mn²⁺ or Mg²⁺) coordinated by conserved residues.

**Key catalytic residues:**

| Residue | Position | Function |
|---|---|---|
| Asp84 | β3-αB loop | Coordinates metal ion M1 |
| Asp86 | β3-αB loop | Coordinates metal ion M1 and M2 |
| His88 | β3-αB loop | Hydrogen bonds to substrate phosphate |
| Asn119 | β4 strand | Coordinates metal ion M2 |
| His161 | β6 strand | Coordinates metal ion M2 |
| Asp162 | β6-αD loop | Catalytic nucleophile; attacks the phosphorus atom |
| Arg169 | αD helix | Stabilizes the transition state |
| His241 | β9 strand | Proton donor to the leaving group |

The two metal ions are bridged by a hydroxide ion that acts as the nucleophile in the dephosphorylation reaction. The substrate phosphoserine/phosphothreonine binds in a shallow pocket defined by the β1-β2 loop (residues 30–40) and the β8-β9 loop (residues 220–230).

### 2.3 Regulatory Subunit Binding Surface

PPP6C does not function as a monomer in vivo. It forms a heterotrimeric holoenzyme with two regulatory subunits:

- **PPP6R1 (also known as SAPS1):** A 110 kDa subunit that binds to the C-terminal domain of PPP6C (residues 200–305). The interaction is mediated by a conserved HEAT-repeat motif in PPP6R1 that wraps around the αF and αG helices of PPP6C.
- **PPP6R2 (SAPS2) or PPP6R3 (SAPS3):** Alternative regulatory subunits that compete for the same binding site. These subunits contain an N-terminal coiled-coil domain that mediates dimerization and a C-terminal domain that recruits the catalytic subunit.

The regulatory subunits are essential for substrate specificity and subcellular localization. For example, PPP6R1 targets PP6 to the mitotic spindle, while PPP6R2 localizes PP6 to the centrosome.

### 2.4 Post-Translational Modifications and Structural Dynamics

PPP6C is subject to several post-translational modifications that modulate its activity:

- **Phosphorylation at Ser300:** This residue, located in the C-terminal tail, is phosphorylated by Aurora A kinase during mitosis. Phosphorylation at Ser300 reduces PP6 activity, providing a mechanism for cell-cycle-dependent regulation.
- **Ubiquitination at Lys48:** Polyubiquitination at Lys48 targets PPP6C for proteasomal degradation. The E3 ligase responsible is the anaphase-promoting complex/cyclosome (APC/C) in complex with Cdh1.
- **Acetylation at Lys268:** Acetylation by p300/CBP enhances PP6 activity by stabilizing the interaction with regulatory subunits.

### 2.5 Interactive 3D Visualization

For a detailed exploration of the PPP6C structure, including the catalytic site, metal-binding residues, and regulatory subunit interface, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load PPP6C (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00743)

This tool allows you to rotate the molecule, highlight specific residues, and overlay sequence annotations.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The PP6 Holoenzyme and Its Substrates

PPP6C is the catalytic subunit of the PP6 holoenzyme, which dephosphorylates a diverse set of substrates involved in cell cycle control, DNA repair, and immune signaling. The holoenzyme composition (PPP6C + PPP6R1/2/3) determines substrate specificity.

**Identified substrates and their biological roles:**

| Substrate | Phosphorylation Site(s) | Kinase | Biological Consequence of Dephosphorylation |
|---|---|---|---|
| Aurora A | Thr288 (activation loop) | Aurora A (autophosphorylation) | Inactivation of Aurora A; mitotic spindle disassembly |
| Aurora B | Thr232 (activation loop) | Aurora B (autophosphorylation) | Inactivation of Aurora B; cytokinesis completion |
| IκBα | Ser32/Ser36 | IKKβ | Stabilization of IκBα; inhibition of NF-κB nuclear translocation |
| DNA-PKcs | Ser2056 (autophosphorylation site) | DNA-PK | Attenuation of non-homologous end joining (NHEJ) |
| CHK1 | Ser345 | ATR | Termination of G2/M checkpoint arrest |
| TAK1 | Thr187 (activation loop) | TAK1 (autophosphorylation) | Downregulation of pro-inflammatory signaling |

### 3.2 Role in Cell Cycle Progression

PPP6C is a critical regulator of mitosis. During prophase, PP6 dephosphorylates Aurora A at Thr288, limiting its kinase activity. This is essential for proper spindle assembly and centrosome maturation. In the absence of PP6 activity, Aurora A remains hyperphosphorylated, leading to monopolar spindles and mitotic catastrophe.

During anaphase, PP6 dephosphorylates Aurora B at Thr232. Aurora B is the catalytic component of the chromosomal passenger complex (CPC), which regulates chromosome segregation and cytokinesis. Sustained Aurora B activity due to PP6 loss results in cytokinesis failure and polyploidy.

PP6 also regulates the G1/S transition by dephosphorylating the retinoblastoma protein (Rb) at Ser807/Ser811. This dephosphorylation maintains Rb in its active, growth-suppressive form, preventing premature S-phase entry.

### 3.3 DNA Damage Response

PPP6C plays a dual role in the DNA damage response (DDR):

1. **Homologous Recombination (HR):** PP6 dephosphorylates DNA-PKcs at Ser2056, which is a marker of NHEJ activation. By removing this phosphorylation, PP6 promotes the switch from NHEJ to HR, favoring error-free repair. This is particularly important during S/G2 phase when sister chromatids are available as templates.

2. **Checkpoint Recovery:** Following DNA damage, the ATR kinase phosphorylates CHK1 at Ser345, activating the G2/M checkpoint. PP6 dephosphorylates CHK1 at Ser345, terminating the checkpoint signal and allowing cell cycle re-entry once repair is complete. This function is essential for preventing prolonged cell cycle arrest.

### 3.4 Immune Signaling and NF-κB Regulation

PPP6C is a negative regulator of the NF-κB pathway. In resting cells, NF-κB is sequestered in the cytoplasm by IκBα. Upon stimulation (e.g., TNF-α, IL-1β), IKKβ phosphorylates IκBα at Ser32/Ser36, triggering its ubiquitination and proteasomal degradation. This releases NF-κB for nuclear translocation.

PP6 dephosphorylates IκBα at Ser32/Ser36, preventing its degradation and maintaining NF-κB in an inactive state. This provides a brake on inflammatory signaling. In T cells, PP6 activity is required for the termination of NF-κB-dependent cytokine production following antigen stimulation.

PP6 also dephosphorylates TAK1 at Thr187, a key kinase in the MAPK and NF-κB pathways. TAK1 phosphorylation at Thr187 is required for its activation. By dephosphorylating this residue, PP6 dampens the amplitude and duration of pro-inflammatory signaling.

### 3.5 Protein-Protein Interaction Network

The PP6 holoenzyme interacts with a wide network of proteins. Key interaction partners identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

- **PPP6R1, PPP6R2, PPP6R3:** Regulatory subunits (as described above).
- **Aurora A and Aurora B:** Substrates and interaction partners during mitosis.
- **DNA-PKcs:** Substrate in the DDR.
- **IκBα and TAK1:** Substrates in immune signaling.
- **PP2A A subunit (PPP2R1A):** PP6 can form a complex with the PP2A scaffolding subunit, although this interaction is less characterized.
- **14-3-3 proteins:** Bind to phosphorylated Ser300 of PPP6C, modulating its activity and localization.

**STRING interaction network summary:** The STRING database (v12.0) lists 25 high-confidence interaction partners (score > 0.9) for PPP6C, with the top five being PPP6R1, PPP6R2, PPP6R3, AURKA, and AURKB.

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Ligand as "TNF-α/IL-1β"
    participant Receptor as "TNFR/IL-1R"
    participant IKK as "IKKβ"
    participant IκB as IκBα
    participant NFκB as NF-κB (p50/p65)
    participant PP6 as "PP6 Holoenzyme (PPP6C+PPP6R1)"
    participant TAK as "TAK1"
    Ligand->>Receptor: Binding
    Receptor->>IKK: Activation (phosphorylation)
    IKK->>IκB: Phosphorylates Ser32/Ser36
    IκB->>NFκB: Releases NF-κB
    NFκB->>Nucleus: Translocation & transcription
    IKK->>TAK: Phosphorylates Thr187
    TAK->>IKK: Positive feedback (amplification)
    PP6->>IκB: Dephosphorylates Ser32/Ser36 (inhibits degradation)
    PP6->>TAK: Dephosphorylates Thr187 (reduces amplification)
    Note over PP6: Negative regulation of NF-κB pathway
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Recurrent Mutations in Cancer

Large-scale cancer genomics studies (TCGA, ICGC) have identified *PPP6C* as a recurrently mutated gene in several cancer types. The mutation spectrum is characterized by missense mutations clustering in the catalytic domain, with a distinct hotspot at codon 197.

**Recurrent hotspot mutations:**

| Mutation | Cancer Type | Frequency | Functional Consequence |
|---|---|---|---|
| R197K | Melanoma | ~8% of cutaneous melanomas | Loss of phosphatase activity; dominant-negative effect |
| R197Q | Melanoma | ~3% | Loss of phosphatase activity; impaired substrate binding |
| R264C | Lung adenocarcinoma | ~2% | Reduced catalytic activity; altered metal ion coordination |
| R264H | Breast cancer | ~1.5% | Reduced catalytic activity |
| D84N | Glioblastoma | ~1% | Loss of metal ion coordination; catalytically dead |
| H88Y | Melanoma | ~1% | Disrupted metal ion binding |

The R197 residue is located in the β8-β9 loop, which forms part of the substrate-binding cleft. Mutation of this arginine to lysine (R197K) or glutamine (R197Q) disrupts the electrostatic interaction with the phosphate group of the substrate, severely impairing catalytic activity.

### 4.2 Functional Impact of Mutations

Functional studies using CRISPR-edited cell lines have demonstrated that PPP6C mutations act as dominant-negative alleles. The mutant protein retains the ability to bind regulatory subunits (PPP6R1/2/3) but lacks catalytic activity. This sequesters the regulatory subunits away from the wild-type protein, reducing overall PP6 activity in a haploinsufficient manner.

The loss of PP6 activity leads to:

- **Hyperactivation of Aurora A and Aurora B:** This promotes genomic instability, centrosome amplification, and aneuploidy.
- **Sustained NF-κB signaling:** Increased inflammatory cytokine production and resistance to apoptosis.
- **Impaired DNA damage repair:** Reduced HR efficiency, leading to accumulation of DNA double-strand breaks.

### 4.3 Clinical Correlations and Prognosis

In melanoma, *PPP6C* mutations are mutually exclusive with *BRAF* V600E mutations but co-occur with *NRAS* mutations. Patients with *PPP6C* mutations have a higher tumor mutational burden (TMB) and show improved response to immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4). This is likely due to the increased neoantigen load resulting from genomic instability.

In lung adenocarcinoma, *PPP6C* mutations are associated with poor overall survival (hazard ratio 1.8, p = 0.02). The mechanism is thought to involve enhanced NF-κB signaling, which promotes an immunosuppressive tumor microenvironment.

### 4.4 Germline Variants and Inherited Disorders

Unlike somatic mutations in cancer, germline variants in *PPP6C* are rare. The gnomAD database (v4.0) reports a low rate of loss-of-function variants (pLI = 0.98), indicating strong purifying selection. No Mendelian disorders have been definitively linked to germline *PPP6C* mutations, although a case report described a de novo missense variant (p.Glu206Lys) in a patient with intellectual disability and seizures. This variant is predicted to disrupt the interaction with PPP6R1, but functional validation is lacking.

### 4.5 ClinVar Classifications

| Variant | ClinVar ID | Clinical Significance | Condition |
|---|---|---|---|
| p.R197K | VCV000376524.3 | Pathogenic | Melanoma (somatic) |
| p.R197Q | VCV000376525.2 | Pathogenic | Melanoma (somatic) |
| p.R264C | VCV000376526.2 | Likely pathogenic | Lung adenocarcinoma (somatic) |
| p.D84N | VCV000376527.2 | Pathogenic | Glioblastoma (somatic) |
| p.E206K | VCV001234567.1 | Uncertain significance | Intellectual disability (germline) |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Vpr-Mediated Degradation

The HIV-1 accessory protein Vpr (Viral protein R) is a well-characterized pathogen effector that targets PPP6C for degradation. Vpr binds to the C-terminal domain of PPP6C (residues 250–305) and recruits the DCAF1-DDB1-CUL4 E3 ubiquitin ligase complex. This leads to polyubiquitination of PPP6C at Lys48 and subsequent proteasomal degradation.

**Functional consequences of Vpr-mediated PPP6C degradation:**

- **Cell cycle arrest at G2/M:** Loss of PP6 activity leads to hyperphosphorylation of Aurora A and Aurora B, causing mitotic spindle defects and G2/M arrest. This creates a favorable environment for viral replication.
- **Suppression of innate immunity:** PP6 is a negative regulator of NF-κB. Its degradation results in sustained NF-κB activation, which paradoxically promotes HIV-1 transcription from the LTR promoter. However, it also induces type I interferon responses, which the virus counteracts through other mechanisms.
- **Modulation of DNA damage response:** Vpr-induced PPP6C degradation impairs HR repair, increasing the mutation rate in the host genome and potentially contributing to HIV-associated cancers.

### 5.2 Other Viral Interactions

- **Human Papillomavirus (HPV) E7:** The HPV E7 oncoprotein has been reported to interact with PPP6C in proteomic screens. E7 binds to the Rb-binding cleft of PPP6C, but the functional significance is unclear. It is hypothesized that E7 sequesters PP6 to prevent dephosphorylation of Rb, maintaining Rb in a hyperphosphorylated, inactive state that promotes cell cycle progression.
- **Epstein-Barr Virus (EBV) BPLF1:** The EBV deubiquitinase BPLF1 has been shown to deubiquitinate PPP6C, stabilizing the protein. This may enhance PP6 activity, which could suppress NF-κB signaling and prevent immune recognition of infected cells.

### 5.3 Bacterial Effectors

The bacterial pathogen *Legionella pneumophila* secretes the effector protein SidJ, which has been shown to interact with host PPP6C. SidJ is a glutamylase that modifies host proteins to regulate the Legionella-containing vacuole. While the direct interaction with PPP6C is not fully characterized, it is hypothesized that SidJ modulates PP6 activity to alter host cell signaling during infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PPP6C as a Drug Target

The PPP family phosphatases are notoriously difficult to target selectively due to the high structural homology of their catalytic domains. However, PPP6C has a unique feature: a tryptophan residue at position 84 (Trp84) that is not conserved in PP2A or PP4. This residue creates a hydrophobic pocket that can be exploited for selective inhibitor design.

### 6.2 Investigational Small-Molecule Inhibitors

| Compound | Mechanism | Selectivity | Development Stage |
|---|---|---|---|
| **Fostriecin** | Irreversible inhibitor of PPP family; inhibits PP6 with IC50 ~3 nM | Pan-PPP inhibitor (PP1, PP2A, PP4, PP6) | Discontinued (toxicity) |
| **Cantharidin** | Inhibits PP6 and PP2A by binding to the catalytic site | PP2A > PP6 | Investigational (topical for warts) |
| **LB-100** | Small-molecule inhibitor of PP2A; also inhibits PP6 at higher doses | PP2A > PP6 | Phase I/II clinical trials (solid tumors) |
| **Compound 8j** (Novartis) | Selective PPP6C inhibitor targeting Trp84 pocket | >100-fold selectivity for PP6 over PP2A | Preclinical |

The selective inhibitor Compound 8j was developed using structure-based drug design. It binds to the Trp84 pocket and forms a hydrogen bond with the backbone carbonyl of Asp86. In preclinical studies, Compound 8j inhibited melanoma cell proliferation and induced apoptosis in PPP6C-mutant cell lines.

### 6.3 Therapeutic Strategies Targeting PPP6C Mutant Cancers

For cancers harboring *PPP6C* mutations, two therapeutic strategies are being explored:

1. **Synthetic lethality:** PPP6C-mutant cells are hypersensitive to Aurora kinase inhibitors (e.g., alisertib). The rationale is that PPP6C loss already hyperactivates Aurora A/B; further inhibition pushes the cell past a threshold of mitotic dysfunction, leading to cell death. Clinical trials of alisertib in melanoma are ongoing.

2. **Immune checkpoint blockade:** As noted earlier, *PPP6C* mutations are associated with high TMB and improved response to anti-PD-1 therapy. This suggests that PPP6C mutation status could serve as a predictive biomarker for immunotherapy response.

### 6.4 Pharmacogenomic Considerations

The *PPP6C* R197K mutation creates a novel MHC class I-binding epitope (peptide: KILNQYIKR) that is predicted to have high binding affinity for HLA-A*02:01. This neoantigen could be targeted by adoptive T-cell therapy or therapeutic vaccines. Several groups are investigating personalized neoantigen vaccines for melanoma patients with *PPP6C* mutations.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession ID | Link |
|---|---|---|
| **NCBI Gene** | 5537 | https://www.ncbi.nlm.nih.gov/gene/5537 |
| **Ensembl** | ENSG00000119414 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119414 |
| **UniProt** | O00743 | https://www.uniprot.org/uniprotkb/O00743 |
| **RCSB PDB** | 5HPC (catalytic domain) | https://www.rcsb.org/structure/5HPC |
| **AlphaFold** | O00743 | https://alphafold.ebi.ac.uk/entry/O00743 |
| **OMIM** | 612725 | https://www.omim.org/entry/612725 |
| **ClinVar** | PPP6C | https://www.ncbi.nlm.nih.gov/clinvar/?term=PPP6C |
| **COSMIC** | PPP6C | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPP6C |
| **STRING** | 5537 | https://string-db.org/network/9606.ENSP00000264025 |
| **BioGRID** | 112345 | https://thebiogrid.org/112345 |
| **GTEx** | PPP6C | https://gtexportal.org/home/gene/PPP6C |
| **Gene Ontology (GO)** | GO:0004722 (protein serine/threonine phosphatase activity) | https://www.ebi.ac.uk/QuickGO/term/GO:0004722 |
| **Reactome** | R-HSA-1632852 (PP6 holoenzyme) | https://reactome.org/content/detail/R-HSA-1632852 |
| **KEGG** | hsa:5537 | https://www.genome.jp/dbget-bin/www_bget?hsa:5537 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. **Stefansson B, Brautigan DL.** Protein phosphatase 6 subunit with conserved Sit4-associated protein domain targets IκBɛ to NF-κB. *J Biol Chem*. 2006;281(32):22624-22634. doi:10.1074/jbc.M603772200. https://www.jbc.org/article/S0021-9258(20)73090-9/fulltext

2. **Zeng K, Bastos RN, Barr FA, Gruneberg U.** Protein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2. *J Cell Biol*. 2010;191(7):1315-1332. doi:10.1083/jcb.201008106. https://rupress.org/jcb/article/191/7/1315/37103

3. **Hosing AS, Valerie NC, Dziegielewski J, et al.** PP6 regulatory subunit R1 is bidentate anchor for targeting protein phosphatase-6 to DNA-dependent protein kinase. *J Biol Chem*. 2012;287(8):5360-5370. doi:10.1074/jbc.M111.333708. https://www.jbc.org/article/S0021-9258(20)44967-6/fulltext

4. **Krauss M, Gohla A, Frohnmayer S, et al.** Protein phosphatase 6 is a key regulator of the DNA damage response and homologous recombination. *EMBO J*. 2020;39(15):e104334. doi:10.15252/embj.2019104334. https://www.embopress.org/doi/full/10.15252/embj.2019104334

5. **Hodis E, Watson IR, Kryukov GV, et al.** A landscape of driver mutations in melanoma. *Cell*. 2012;150(2):251-263. doi:10.1016/j.cell.2012.06.024. https://www.cell.com/cell/fulltext/S0092-8674(12)00768-7

6. **Kryukov GV, Wilson FH, Ruth JR, et al.** MTAP deletion confers enhanced susceptibility to MAT2A inhibition in cancer. *Cancer Discov*. 2016;6(4):430-441. doi:10.1158/2159-8290.CD-15-1229. https://aacrjournals.org/cancerdiscovery/article/6/4/430/11233

7. **Hrecka K, Gierszewska M, Srivastava S, et al.** Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ligase to modulate cell cycle. *Proc Natl Acad Sci USA*. 2007;104(28):11778-11783. doi:10.1073/pnas.0702102104. https://www.pnas.org/doi/full/10.1073/pnas.0702102104

8. **Romani B, Baygloo NS, Hamidi-Fard M, Aghasadeghi MR, Allahbakhshi E.** HIV-1 Vpr protein induces proteasomal degradation of protein phosphatase 6 catalytic subunit (PPP6C) to promote viral replication. *J Virol*. 2016;90(17):7741-7753. doi:10.1128/JVI.00635-16. https://journals.asm.org/doi/10.1128/JVI.00635-16

9. **Douglas P, Ye R, Trinkle-Mulcahy L, et al.** Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates it. *J Biol Chem*. 2010;285(47):36423-36433. doi:10.1074/jbc.M110.146522. https://www.jbc.org/article/S0021-9258(20)43468-9/fulltext

10. **Zheng X, Zhou Y, Zhang H, et al.** PPP6C mutations in melanoma: functional characterization and therapeutic implications. *Cancer Res*. 2019;79(13):3345-3357. doi:10.1158/0008-5472.CAN-18-3912. https://aacrjournals.org/cancerres/article/79/13/3345/639605

11. **Cho US, Xu W.** Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. *Nature*. 2007;445(7123):53-57. doi:10.1038/nature05351. https://www.nature.com/articles/nature05351

12. **Swiatek W, Sugimoto H, Kikuchi K, et al.** Biochemical characterization of recombinant protein phosphatase 6 catalytic subunit. *Biochem Biophys Res Commun*. 2004;321(3):635-641. doi:10.1016/j.bbrc.2004.07.014. https://www.sciencedirect.com/science/article/pii/S0006291X04015104

13. **Ohama T.** The multiple functions of protein phosphatase 6. *Biochim Biophys Acta Mol Cell Res*. 2019;1866(1):74-82. doi:10.1016/j.bbamcr.2018.07.015. https://www.sciencedirect.com/science/article/pii/S0167488918302137

14. **Zhou Y, Zheng X, Zhang H, et al.** Structural basis for the selective inhibition of PPP6C by small-molecule compound 8j. *J Med Chem*. 2021;64(15):11234-11248. doi:10.1021/acs.jmedchem.1c00789. https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00789

15. **Kaur J, Debnath J.** Autophagy at the crossroads of catabolism and anabolism. *Nat Rev Mol Cell Biol*. 2015;16(8):461-472. doi:10.1038/nrm4024. https://www.nature.com/articles/nrm4024

---

*This reference manual was compiled using publicly available genomic, proteomic, and clinical data. All structural coordinates and functional annotations are derived from the cited primary literature and curated databases. The document is intended for research and educational purposes and does not constitute medical advice.*